# Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

> **NCT03912532** · PHASE2 · COMPLETED · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 171 (actual)

## Conditions studied

- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **BIOLOGICAL:** NGM282
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03912532
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-16
- **Primary completion:** 2021-03-04
- **Final completion:** 2021-03-29
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912532, "Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03912532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*